


# Biodefense: Complementary Roles within DHHS


---

**CDC**




- Surveillance and Detection
- Train Local Response Teams
- Maintain Vaccine/Antimicrobial Stockpiles

**NIH**




- Conduct Basic Research
- Develop Medical Interventions
- Develop Research Infrastructure

**FDA**




- Regulatory Approval
  - Vaccines
  - Therapeutics
  - Diagnostics

**OPHEP**



- HHS-Wide Coordination of Emergency Preparedness Activities

# NIH Biodefense Research Funding, FY 2000-2006



\*Does not include \$47.4M in HHS FYs 2005 and 2006 for nuclear/radiobiology defense research and \$50M in FY 2006 for chemical defense research.



## NIAID Strategic Plan for Biodefense Research



## NIAID Biodefense Research Agenda for CDC Category A Agents



## NIAID Biodefense Research Agenda for CDC Category A Agents

### Progress Report



August 2003



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

### Progress Report



June 2004



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens



January 2003



**Therapeutics**




**Vaccines**



**Diagnostics**

**Biodefense  
Research  
Priorities**




**Basic Research  
(including Genomics)**



**Expansion of  
Research Capacity**


# Expansion of Biodefense Research Capacity

---



# Basic Research in Biodefense: Progress and Priorities

---



# Countermeasure Development: Key Achievements

---

## Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir

## Anthrax

- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies

# **Countermeasure Development: Key Achievements (continued)**

---

## **Ebola**

- **Vaccine in human trials at NIAID Vaccine Research Center**

## **Botulinum Toxin**


- **Development of vaccine and monoclonal/polyclonal antibodies**

## **Influenza**

- **Development of vaccines against potential pandemic strains**

# Countermeasure Development: A Changing Paradigm

---



# San Francisco Chronicle

NORTHERN CALIFORNIA'S LARGEST NEWSPAPER

---

FEBRUARY 18, 2002

---

## *Bioterror Funds a Boon for Public Health*

**Experts say research will apply to  
fighting infectious diseases**

# Global Examples of Emerging and Re-Emerging Infectious Diseases

